Abiopharma

Research Shows Medtechs Prioritizing Site Collaboration and Data Quality

Passage Bio, Inc. - Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease

Altimmune Announces Second Quarter 2025 Financial Results and Business Update

Tilray Expands Hemp-Derived Delta-9 THC Beverage Lineup with 10mg Drinks from Fizzy Jane’s and Happy Flower Brands

Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial ofAXPAXLI™ in NPDR

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues

New Form 8-K - VERU INC. Filed: 2025-08-12 AccNo: 0001193125-25-178463 Size: 258 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - GLAUKOS Corp Filed: 2025-08-12 AccNo: 0001558370-25-011142 Size: 5 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - Passage BIO, Inc. Filed: 2025-08-12 AccNo: 0001558370-25-011143 Size: 5 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Bruker - Bruker Announces Quarterly Dividend

New Form 10-Q - Milestone Pharmaceuticals Inc. Filed: 2025-08-12 AccNo: 0001558370-25-011141 Size: 7 MB